Fosnetupitant Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Fosnetupitant Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Fosnetupitant can convert its Small molecule drug profile and NK1R biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Fosnetupitant (query alias: Fosnetupitant) |
|---|---|
| Modality / target | Small molecule drug; NK1R; NK1R antagonists |
| Highest global status | Approved |
| Originator | Helsinn Healthcare SA |
| Active developers | Helsinn Healthcare SA, Taiho Pharmaceutical Co., Ltd. |
The MCP disease footprint includes Chemotherapy-induced nausea and vomiting, Nausea, Vomiting. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT06840769 | Phase 1 | Terminated | 50 | Study Part A: Number of Treatment-emergent Adverse Events |
| JPRN-jRCT1030230130 | Not Applicable | Recruiting | 100 | がん化学療法開始後336時間までの悪心嘔吐完全抑制率（がん化学療法1コース目のみ） |
| JPRN-jRCT1061250083 | Not Applicable | 募集中 | 20 | mFOLFIRINOX療法開始120時間後までのCR率 （CR率：Complete Response率、嘔吐完全抑制率、薬剤投与後に嘔吐がなく、追加で制吐剤を使用しなかった症例の割合） |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase I, Open Label, Single Dose, Two Parts Study in Male and Female Healthy Subjects to Assess the Safety and Pharmacokinetics of Fosnetupitant 235 mg Administered as IV Bolus and of Derived Netupitant and Netupitant Metabolites
Phase 1; n=50; evaluation: not stated. Reported fields: -; Study Part A: Number of Treatment-emergent Adverse Events = 3 Number of TEAE ; -
556P - A prospective observational study to compare the antiemetic efficacy of fosnetupitant + palonosetron vs oral aprepitant + palonosetron
Not Applicable; n=150; evaluation: Positive. Reported fields: Grade ≥2 nausea or vomiting = 18 % ; Grade ≥2 nausea or vomiting = 3.3 %
1879P - Effectiveness of intravenous fosnetupitant & palonosetron for cinv prophylaxis in patients receiving highly emetogenic chemotherapy regimens: Subgroup analysis from a phase IV Indian study
Phase 4; n=178; evaluation: Positive. Reported fields: Adverse Event: headache = 4, 2.25%
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Fosnetupitant addresses Chemotherapy-induced nausea and vomiting, Nausea, Vomiting. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 32 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: NK1R records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-02-11 | Helsinn and MagnaPharm enter long-term agreement for AKYNZEO® and ALOXI® across five Central and Eastern European countries | Approved | Financial terms not disclosed |
| 2025-12-09 | ProBioGen and Spica Therapeutics Announce Collaboration on GlymaxX-Enhanced CLD for Spica’s Clinical Development Candidate ST101 | Preclinical | Financial terms not disclosed |
| 2025-06-03 | Alto Neuroscience acquire a dopamine agonist combination product for treatment-resistant depression through a deal with Chase Therapeutics | Phase 2 | US$1.8M upfront; US$71.5M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
